Ascendis Pharma A (ASND) Return on Sales [ROS] (2014 - 2026)
Ascendis Pharma A (ASND) recorded Return on Sales [ROS] of 64.98% in the quarter ended Jun 30, 2026, up 98.48 percentage points from -33.50% a year earlier and up 54.92 percentage points from the prior quarter.
Ascendis Pharma A (ASND) Return on Sales [ROS] (2014 - 2026) Analysis & Trends
On a TTM basis, Ascendis Pharma A's Return on Sales [ROS] came in at 25.36% as of Jun 30, 2026, up 76.89 percentage points year-over-year; for the year ended Dec 31, 2025, it came in at -18.92%, up 49.78 percentage points from the prior year.
- Annual Return on Sales [ROS] has increased for four straight years, with a five-year change of +4736.15 percentage points (years ended Dec 2020 to Dec 2025).
- Across earlier years, Return on Sales [ROS] came in at -68.70% in the year ended Dec 31, 2024 (+102.10 pp), -170.79% in the year ended Dec 31, 2023 (+927.06 pp), -1097.85% in the year ended Dec 31, 2022 (+4710.74 pp) and -5808.59% in the year ended Dec 31, 2021 (-1053.52 pp).
- The figure for the quarter ended Jun 30, 2026 is the highest quarterly Return on Sales [ROS] in data going back to the quarter ended Mar 31, 2014.
- On a year-over-year basis, Return on Sales [ROS] has increased for five consecutive quarters, with an average year-over-year change of +99.69 percentage points over the last eight quarters.
- Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 14834.06 percentage points in the quarter ended Mar 31, 2022, against a drop of 5849.99 percentage points in the quarter ended Sep 30, 2021 at the low end.
- Per Business Quant, the preceding three quarters came in at 10.06% (quarter ended Mar 31, 2026), 4.00% (quarter ended Dec 31, 2025) and 5.15% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Ascendis Pharma A | 14.12 Bn | 10.37 Bn | 362.22 Mn | 64.98% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.98% |
| Mar 31, 2026 | 10.06% |
| Dec 31, 2025 | 4.00% |
| Sep 30, 2025 | 5.15% |
| Jun 30, 2025 | -33.50% |
| Mar 31, 2025 | -103.23% |
| Dec 31, 2024 | 0.22% |
| Sep 30, 2024 | -167.28% |
| Jun 30, 2024 | -370.18% |
| Mar 31, 2024 | -51.25% |
| Dec 31, 2023 | -12.09% |
| Sep 30, 2023 | -279.82% |
| Jun 30, 2023 | -297.17% |
| Mar 31, 2023 | -427.77% |
| Dec 31, 2022 | -643.75% |
| Sep 30, 2022 | -945.09% |
| Jun 30, 2022 | -2,303.46% |
| Mar 31, 2022 | -1,875.06% |
| Dec 31, 2021 | -130.71% |
| Sep 30, 2021 | -8,709.07% |
Ascendis Pharma A Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();